Signals Blog
Menu

Cell Therapy Deal Review: November

Welcome to your Cell Therapy Deal Review for the month of November. Astellas failed to achieve the majority share it needed to push through a takeover of Ocata Therapeutics valued at $379 million. ImmunoCellular Therapeutics announced a research agreement with MD...

ISCT webinar: Reimbursement re-cap

For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on...

Right Turn Special Report: Competition rife in Canada

This may come as a shock to many of you, but the land of lakes, trees, socialism and universal healthcare has a dark underbelly: the competitive nature of its academics. If you look to the regenerative medicine community, everything looks hunky-dory and, on the...

Rudolph, red noses and regeneration

Samantha Payne is a PhD student in the Chemical Engineering and Applied Chemistry department at the University of Toronto. She has previously investigated regeneration in a non-mammalian gecko model during an MSc program, and now currently combines stem cell biology...

Right Turn: The official Signals Gift Giving Guide

Emily Easto, communications specialist for the Centre for Commercialization of Regenerative Medicine (CCRM), is making her Signals debut here. If you like her list, we can probably coax her into making it a yearly offering. While publishing a gift guide so late in the...